Skip to main content
NCBI home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2026 Feb 23;17:1687439. doi: 10.3389/fphar.2026.1687439

Different treatments for Crohn’s disease complicated by severe acute lower gastrointestinal bleeding: infliximab therapy is critical and cannot be ignored

Shuoyi Yao 1,2,†, Zheyu Wang 1,2,†, Mingyan Xie 3, Shengnan Wu 4, Yingjuan Feng 5, Xiaoming Liu 1,2, Fen Wang 1,2,*
PMCID: PMC12967973  PMID: 41808876

Abstract

Objective

Acute severe lower gastrointestinal bleeding (SLGIB) is one of the life-threatening complications of Crohn’s disease (CD) whose therapy is being optimized constantly. We aim to evaluate the therapeutic efficacies and economic benefits of different treatments for acute SLGIB in CD.

Method

A multicenter retrospective cohort study was conducted in Hunan Province of China on CD patients with acute SLGIB; here, we analyzed the clinical (hemostatic effects, hemoglobin improvement, rebleeding risk, anti-inflammatory influence, and complications) and economic (duration and cost of hospital stay) characteristics of infliximab, surgical, and traditional hemostatic therapies.

Results

All three groups showed no obvious signs of bleeding in the first week. The negative conversion rates of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in the infliximab therapy group were significantly higher than those in the other two groups (adjusted-p < 0.05 for both CRP and ESR), while the increase in hemoglobin did not differ significantly among the three groups (p = 0.298). The incidence of post-treatment complications was significantly higher in the surgery (resection) group than the other two groups (adjusted-p < 0.05). Cumulative rebleeding risk was lowest in the infliximab therapy group (p = 0.001 vs. surgery and p = 0.032 vs. traditional therapy). The multivariate COX regression also revealed that surgery [hazard ratio (HR) = 7.270, 95% confidence interval (CI): (1.574, 33.592), p = 0.011] and traditional therapy [HR = 4.395, 95% CI: (1.011, 19.113), p = 0.048] were independently related to higher rebleeding risk than infliximab therapy. The duration and cost of hospital stay of the infliximab therapy group were significantly lower than those of the surgery group (adjusted-p < 0.05) and similar to those of the traditional therapy group (adjusted-p > 0.05).

Conclusion

Compared to surgery and traditional therapy (such as somatostatins or octreotide), infliximab therapy could control acute SLGIB in CD as well as achieve similar improvement in hemoglobin level with additional anti-inflammatory effects and lower rebleeding risk. Furthermore, infliximab therapy was found to be more economical than surgery.

Keywords: Crohn’s disease, hemostatic therapy, infliximab, lower gastrointestinal bleeding, surgery

Introduction

Crohn’s disease (CD) is an intestinal idiopathic chronic immune-related inflammatory disease that has higher prevalence in western countries (Cassol et al., 2022; Omede et al., 2025). It is reported that the prevalence of CD in the United States increased from 56 per 100,000 persons in 2010 to 165 per 100,000 persons by 2019 (Hutfless et al., 2024). Furthermore, reasons like changes in the dietary customs have increased the prevalence of CD Asia, South America, and Africa (Cassol et al., 2022; Omede et al., 2025; Park and Cheon, 2021; Balderramo et al., 2021). The incidence of acute severe lower gastrointestinal bleeding (SLGIB) in CD ranges from 0.6% to 6% (Lee et al., 2018; Tu et al., 2024), but the associated mortality rate could be as high as 14.3% (Tu et al., 2024) along with high rebleeding risk (19.0%–50.5%) (Lee et al., 2018; Tu et al., 2024). Hence, acute SLGIB is a serious life-threatening complication of CD whose treatment is being optimized constantly. When acute SLGIB occurs in CD patients, they can choose the conventional hemostatic therapy, but approximately 4.3%–7.6% of patients opt for surgery given the ineffectiveness of medications (Tu et al., 2024). A study by Kim et al. (2012) showed that even under standard treatment, the cumulative rebleeding rate in CD was 33.0% after 1 year and reached almost 72.3% after 10 years. In the treatment of CD, aside from clinical efficacy, we need to carefully consider factors like complications, recurrence, as well as duration and expenses associated with hospitalization (Sands et al., 2024).

Nowadays, the available treatment options for CD include biologics like infliximab, adalimumab, and ustekinumab (Baumgart and Le Berre, 2021), which have exhibited promising efficacy in controlling the progression of CD. In a network meta-analysis, infliximab showed the best efficacy at inducing clinical remission among all agents (Attauabi et al., 2024). According to another meta-analysis based on model stimulation, 44.44% of patients using infliximab achieved clinical remission, while the placebo effect was approximately 21.26%. The clinical response rate of infliximab was reportedly 67.49%, which is the highest, followed by adalimumab (60.34%), with the placebo effect achieving a response rate of 39.48% (Yu et al., 2022). Treatment options using biologics could also reduce the need for surgery in CD patients (Jenkinson et al., 2020). Despite infliximab showing the best efficacy among different biologic agents, very few studies have evaluated the efficacy of infliximab treatment for CD complicated by acute SLGIB, and none of these works have focused on the economic perspective. Therefore, we retrospectively analyzed the therapeutic efficacies and economic benefits of infliximab, surgical, and conventional hemostatic treatments to fill this gap in literature through a multicenter study conducted in Hunan Province of China.

Methods

Patient population

Our multicenter retrospective cohort study was performed using data collected from CD patients with acute SLGIB who received infliximab treatment, surgery (resection of lesion parts), or conventional hemostatic therapy (such as somatostatins or octreotide) (Tamagno et al., 2004; Bon et al., 2012; Lavy and Yasin, 2003) between January 2012 and June 2025 at the Third Xiangya Hospital of Central South University, First People’s Hospital of Changde City, Yueyang Central Hospital, and Second Affiliated Hospital of University of South China. This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Third Xiangya Hospital of Central South University (no. I 22153). Owing to the retrospective nature of the study, the Clinical Research Ethics Committee of the Third Xiangya Hospital of Central South University waived the need to obtain informed consent from the participants.

The diagnosis of CD was confirmed through the symptoms, the inflammatory indicators, imaging, endoscopy, and pathology. As noted by Yoon et al. (2021), acute SLGIB was defined as an acute overt lower gastrointestinal bleeding that resulted in (i) an abrupt decrease in hemoglobin (Hb) level to below 9 g/dL or at least 2 g/dL below the baseline, and/or (ii) transfusion of at least two units of blood within 24 h. Patients were excluded from the study if their bleeding incidence was in the upper gastrointestinal tract or caused by hemorrhoids or if they did not meet the criteria for diagnosis of acute SLGIB.

Data collection

The patient medical records were reviewed retrospectively, and the following data were extracted: gender, date of bleeding, age at the time of first bleeding, Montreal classification of CD, disease duration of CD at the time of bleeding, Crohn’s Disease Activity Index (CDAI) value, smoking history, information on blood transfusion, Hb level, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values before/after the treatment of bleeding, medical treatments of CD before/after bleeding, albumin level at the time of discharge after first bleeding, treatment of bleeding, complications after bleeding treatment, duration of hospitalization, and hospitalization costs. All patients were followed up to record the hemostatic effects and rebleeding rates. The bleeding site was defined as the exact bleeding locus detected by colonoscopy, radionuclide bleeding scan, or angiography (including computed tomography angiography). The treatment was considered successful if there were no obvious signs of bleeding during the time of discharge or the fecal occult blood test result was negative. As per Kim et al. (2021), rebleeding was defined as the occurrence of overt bleeding that satisfied the criteria for acute SLGIB after being discharged.

Statistical analyses

The median and interquartile range (IQR) values were calculated to describe non-normal continuous variables, whereas normal variables were expressed using the mean and standard deviation (SD). The chi-squared test or Fisher’s exact test was used for categorical variables, and the Kruskal–Wallis test (for non-normal variables) or ANOVA (for normal variables) was used for continuous variables to compare the demographic and clinical characteristics of the three groups. Risk of rebleeding was analyzed using the Kaplan–Meier method. To explore the possible factors related to rebleeding, we performed univariate and multivariate COX regressions, where variables with p-values < 0.1 in the univariate analysis were included in the multivariate analysis. We also calculated the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs), with p-values < 0.05 being considered as statistically significant. All statistical analyses were performed using SPSS 26.0 software.

Results

Baseline characteristics of the patients

A total of 88 CD patients were included in this study who experienced acute SLGIB for the first time; their median follow-up time was 646.5 days, and the patients were grouped into infliximab treatment (n = 24), surgery (n = 19), and traditional treatment (n = 45) groups. Most of the patients in the three groups were male, and the mean age of the infliximab group was lower than those of the other two groups. The ileum was the most common location for CD, and the bleeding sites of the patients were consistent with the CD lesion parts. There was no significant difference among the three groups in terms of baseline Hb, CRP, and albumin levels. The distribution of localized or diffused bleeding among the three groups was not significantly different. The traditional therapy group had the lowest baseline ESR and highest CDAI values among the groups. The detailed baseline characteristics of the patients are listed in Table 1.

TABLE 1.

Baseline characteristics of the patients included in this study.

Characteristic Infliximab therapy group (n = 24) Surgery group (n = 19) Traditional therapy group (n = 45) p-value
Male sex, % 75.0 78.9 91.1 0.180
Age (SD), years 25.54a (8.53) 38.95b (16.84) 32.22b (10.74) 0.003
Active smoker, % 8.3a 42.1b 22.2a,b 0.032
Montreal classification, %
 A1 16.7a 15.8a 13.3a 0.038
 A2 83.3a 52.6a 66.7a ​
 A3 0.0a 31.6b 20.0a,b ​
 B1 50.0 31.6 51.1 0.343
 B2/B3 50.0 68.4 48.9 ​
 L1 41.7 47.4 48.9 0.299
 L2 16.7 31.6 11.1 ​
 L3 41.7 21.1 40.0 ​
Disease duration (IQR), years 0.04 (2.74) 0.03 (1.93) 0.13 (3.17) 0.463
Receiving blood transfusion, % 91.7 78.9 71.1 0.135
Amount of blood transfusion (IQR), unit 4 (3) 4 (3) 5 (2) 0.792
Hb (IQR), g/dL 8.0 (2.0) 7.0 (1.3) 7.1 (2.6) 0.235
CRP (IQR), mg/L 49.14 (46.52) 31.00 (33.14) 35.32 (64.71) 0.288
ESR (IQR), mm/h 47b (20) 41b (33) 24a (14) 0.001
CDAI (SD) 175.56a (21.45) 178.65a (22.83) 204.25b (26.57) <0.001
Treatment before bleeding, % ​ ​ ​ 0.019
 No treatment 16.7a 57.9b 48.9b ​
 Infliximab therapy 16.7a 0.0a 6.7a ​
 Non-biologic therapy 66.7a 42.1a 44.4a ​
Localized bleeding, % 58.3 73.7 51.1 0.247
Diffused bleeding, % 41.7 26.3 48.9
Albumin (IQR), g/L 42.7 (8.4) 43.4 (8.1) 43.8 (9.4) 0.759
Open in a new tab

a, b: subsets with the same superscript letters did not differ significantly from each other (adjusted-p > 0.05), while differences between those with different superscript letters were significant (adjusted-p < 0.05). Non-biologic therapies included azathioprine, mesalazine, prednisone, salazosulfapyridine, and methylprednisolone. The bold values mean the p values were statistically significant.

For surgery and traditional groups, 57.9% and 48.9% of the respective patients did not receive any therapy before bleeding, while this value was only 16.7% for the infliximab group. Among the three groups, patients who had received infliximab treatment before bleeding were more likely to choose infliximab therapy directly in the event of acute SLGIB; however, patients who had not received any treatment before were more likely to choose surgery or traditional therapy (Table 1). All the patients in the infliximab group continued infliximab therapy after hemostasis, while only 31.6% of patients in the surgery and 35.6% of patients in the traditional therapy groups received infliximab therapy afterward (Table 2). None of the patients received surgery during the follow-up period.

TABLE 2.

Outcomes and post-bleeding treatment in each group.

Variable Infliximab therapy group Surgery group Traditional therapy group p-value
CRP negative conversion rate, % 77.8a 23.5b 21.2b <0.001
ESR negative conversion rate, % 71.4a 23.5b 19.4b 0.002
Increase in Hb level (SD), g/dL 2.0 (3.1) 2.8 (1.6) 2.2 (1.3) 0.298
Patients with complications after treatment 0.0a 78.9b 6.7a <0.001
Total duration of hospitalization (IQR), days 7a (5) 24b (11) 11a (5) <0.001
Total cost of hospitalization (IQR), CNY 12,458.67a (7,581.53) 59,764.65b (24,256.54) 12,945.23a (11,606.06) <0.001
Treatment after bleeding, % ​ ​ ​ <0.001
 No treatment 0.0a 31.6b 20.0a,b ​
 Infliximab therapy 100.0a 31.6b 35.6b ​
 Non-biologic therapy 0.0a 36.8b 44.4b ​
Open in a new tab

a, b: subsets with the same superscript letters did not differ significantly from each other (adjusted-p > 0.05), while differences between those with different superscript letters were significant (adjusted-p < 0.05). C-reactive protein (CRP), negative: < 5 mg/L. Erythrocyte sedimentation rate (ESR), negative: <20 mm/h for women; <15 mm/h for men. CNY, Chinese Yuan. Non-biologic therapies included azathioprine, mesalazine, prednisone, salazosulfapyridine, and methylprednisolone. The bold values mean the p values were statistically significant.

Therapeutic efficacy of each group

In all three groups, the bleeding became unobvious within 1 week of treatment. The negative conversion rates of CRP and ESR were higher in the infliximab therapy group (77.8% for CRP and 71.4% for ESR) than the surgery (23.5% for CRP and 23.5% for ESR) and traditional therapy (21.2% for CRP and 19.4% for ESR) groups and were statistically significant (adjusted-p < 0.05 for both CRP and ESR). There was no significant difference in Hb level increase among the three groups (p = 0.298), implying that the three treatment types examined here have similar effects on Hb improvement (Table 2). In terms of post-treatment complications, the surgery group had the highest rate; there were no complications in any of the patients receiving infliximab therapy. In the surgery group, 15 patients reportedly showed intestinal fistula, intestinal obstruction, wound bleeding, or wound infection after treatment; furthermore, three patients in the traditional therapy group developed adverse reactions (two had interbowel abscess and one had intestinal fistula). The duration of hospitalization and associated costs were significantly lower in the infliximab therapy group than the surgery group (adjusted-p < 0.05) and similar in the traditional therapy group (adjusted-p > 0.05) (Table 2).

We also performed subgroup analysis for patients with localized and diffused bleeding. In the localized bleeding group, the negative conversion rates of CRP and ESR were higher for infliximab therapy but not significant given the limited sample sizes. The increase in Hb level remained similar among the three groups. In terms of complications as well as duration and cost of hospitalization, the results were similar to those in the general study population, with the surgery group having the highest values in these three aspects (Supplementary Table S1). In the diffused bleeding group, the outcomes were similar to the general results (Supplementary Table S2).

Rebleeding risk of each group

During follow-up, rebleeding was reported by 36 patients (infliximab therapy: 2, surgery: 11, traditional therapy: 23). The rebleeding risk in the infliximab therapy group was significantly lower than those in the surgery (p = 0.001) and traditional therapy (p = 0.032) groups; however, the difference between the surgery and traditional therapy groups was not significant (p = 0.084) (Figure 1). To further explore the factors related to rebleeding, we performed univariate COX regression with the factors shown in Table 3 and included factors with p < 0.1 in the multivariate analysis. We found that the treatment for bleeding was an independent factor related to rebleeding; thus, compared to infliximab therapy, surgery [HR = 7.270, 95% CI: (1.574, 33.592), p = 0.011] and traditional therapy [HR = 4.395, 95% CI: (1.011, 19.113), p = 0.048] had relatively higher risk of rebleeding. Moreover, the Montreal classification of B1 was a predictive factor of rebleeding (Table 3). The localized/diffused bleeding status and albumin level are not related with rebleeding risk.

FIGURE 1.

Kaplan-Meier line graph comparing cumulative risk of re-bleeding over time among infliximab therapy, surgery, and traditional therapy groups, with infliximab group showing the lowest risk and censored data indicated by short marks on each line.

Open in a new tab

Cumulative risk of rebleeding in the different study groups.

TABLE 3.

Results of COX regression on potential factors related to rebleeding.

Parameter Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age, year 0.995 [0.966, 1.025] 0.744 ​ ​ ​
Male sex 1.623 [0.571, 4.615] 0.364 ​ ​ ​
Smoking 1.862 [0.920, 3.768] 0.084 1.150 [0.553, 2.395] 0.708
With post-treatment complication 1.408 [0.655, 3.029] 0.381 ​ ​ ​
Post-bleeding treatment
 No treatment 1 ​ ​ ​ ​ ​
 Infliximab therapy 0.958 [0.308, 2.979] 0.941 ​ ​ ​
 Non-biologic therapy 1.757 [0.589, 5.237] 0.312 ​ ​ ​
Treatment for bleeding
 Infliximab therapy 1 ​ ​ 1 ​ ​
 Surgery 8.509 [1.878, 38.565] 0.005 7.270 [1.574, 33.592] 0.011
 Traditional therapy 4.540 [1.053, 19.582] 0.042 4.395 [1.011, 19.113] 0.048
Montreal classification
 A1 1 ​ ​ ​ ​ ​
 A2 0.864 [0.367, 2.032] 0.737 ​ ​ ​
 A3 1.388 [0.432, 4.462] 0.582 ​ ​ ​
 B1 1 ​ ​ 1 ​ ​
 B2/B3 2.489 [1.187, 5.219] 0.016 2.202 [1.022, 4.746] 0.044
 L1 1 ​ ​ ​ ​ ​
 L2 0.919 [0.306, 2.759] 0.880 ​ ​ ​
 L3 1.190 [0.573, 2.473] 0.641 ​ ​ ​
Disease duration, years 0.927 [0.808, 1.063] 0.279 ​ ​ ​
CDAI 0.993 [0.981, 1.004] 0.212 ​ ​ ​
Receiving blood transfusion 0.603 [0.297, 1.224] 0.161 ​ ​ ​
Localized bleeding 1 ​ ​ ​ ​ ​
Diffused bleeding 0.567 [0.276, 1.166] 0.123 ​ ​ ​
Albumin, g/L 1.009 [0.942, 1.080] 0.805 ​ ​ ​
Open in a new tab

Non-biologic therapies included azathioprine, mesalazine, prednisone, salazosulfapyridine, and methylprednisolone. The bold values in the univariate analysis mean the p values were less than 0.1, which could be included in the multivariate analysis. The bold values in the multivariate analysis mean the p values were statistically significant.

Discussion

In this study, we investigated the efficacies of different therapies for acute SLGIB in CD using a well-defined hospital-based inception cohort, with particular focus on whether infliximab therapy was more advantageous from the clinical and economic perspectives. To the best of our knowledge, this is a pilot effort on evaluating the efficacies, financial constraints, and prognosis of different therapies for acute SLGIB in CD. Our results demonstrate that infliximab therapy could achieve similar bleeding-healing effects as surgery and traditional therapy and that it may also offer anti-inflammatory advantages. With regard to patient safety, the surgery group showed the highest incidence rate of post-treatment complications among the three groups, while the post-treatment complication rates in the infliximab and traditional therapy groups were similar. In terms of the duration and costs of hospitalization, the surgery group had the highest values while the other two groups were similar and not significantly different. During follow-up, the infliximab therapy group reported the lowest risk of rebleeding; the COX regression analysis showed that surgery and traditional therapy could increase the risk of rebleeding compared to infliximab therapy.

In our study, the proportion of patients with CD of the ileum was the highest, which is related to the fact that inflammatory factors are more pronounced in the ileum. Studies have reported that creeping fat exists in patients with CD of the ileum (Atreya and Siegmund, 2021); as one of the sources of inflammation (Suau et al., 2022), creeping fat has garnered extensive attention in recent times. Studies have shown that patients with CD of the ileum require higher drug plasma concentrations to achieve mucosal healing (Takenaka et al., 2021) and that different lesion sites result in different manifestations and prognosis (Atreya and Siegmund, 2021). In the present study, the location of CD did not influence the risk of rebleeding.

The incidence of post-treatment complications was highest in the surgery group. We suggest that this could be related to the release of local inflammatory factors, intestinal anatomy changes after surgery, and proficiency of the surgeon. The CD lesions show segmental distribution. Patients with acute SLGIB are more prone to multiple deep ulcers such that extensive bowel resection could cause short bowel syndrome. Moreover, the highly inflammatory state of the intestine itself is not conducive to postoperative anastomotic healing, which is more likely to cause postoperative intestinal stenosis and intestinal fistula. A study conducted in Japan on 1,871 CD patients who received surgery reported that the 5- and 10-year reoperation rates were 23.4% and 48.0%, respectively; perianal disease and ileocolic CD could increase the risk of reoperation, while anti-TNF therapy after surgery could decrease this risk (Shinagawa et al., 2020). Another research from Denmark showed similar results among 631 initially resected patients, with the 1-, 5-, and 10-year reoperation rates being 12.6%, 22.4%, and 32.2%, respectively, and the main reasons for reoperation being disease activity and stoma reversal (Poulsen et al., 2024).

The rebleeding risk in the infliximab group was significantly lower than those in the surgery and traditional therapy groups. This is attributable to the inhibition of inflammatory reactions in the infliximab therapy group that disrupts the development of CD. The main feature of CD is inflammation of the gastrointestinal tract resulting from the interactions among genes, gut microbiota, and environmental factors (Narula et al., 2023). Traditional medications like somatostatins or octreotide can only control bleeding symptomatically and temporarily. However, infliximab therapy can inhibit immunity, reducing infiltration by local inflammatory factors and promoting rapid mucosal healing (Baumgart and Le Berre, 2021). We also noted that patients with B1 Montreal classification were less likely to rebleed; the reason for this could be that B1 in the Montreal classification implies a non-narrow and non-penetrating condition, which indicates a less-severe disease status.

Despite these findings, there remained a small proportion of patients who experienced rebleeding after infliximab therapy, which could be related to high drug clearance and insufficient drug exposure; in this regard, Gibson et al. (2015) considered the concept of accelerated infliximab induction treatment. For acute severe ulcerative colitis patients with poor drug response, Gibson et al. (2020) reported the use of accelerated dosing of infliximab. Accelerated infliximab induction was also reported for the treatment of CD with acute SLGIB (Zeng et al., 2022), so it may be applicable in CD patients with acute SLGIB showing poor initial responses. Aside from traditional hemostatic therapy, surgery, and infliximab, interventional treatment for bleeding is also developing rapidly at present. However, the diverse lesion sites of CD in patients mean that there may be more than one potential bleeding location, which is a challenge when selecting the embolization site. In transarterial embolization for acute lower gastrointestinal bleeding, there is still a risk of rebleeding (20.7%) and post-embolization ischemia (7.5%) (Yu et al., 2024).

We explored published English literature and found 17 cases of CD-related acute SLGIB from nine studies that reported treatment with infliximab (Zeng et al., 2022; Akazawa et al., 2014; Ando et al., 2009; Aniwan et al., 2012; Belaiche and Louis, 2002; Cunningham et al., 2014; Meyer and Levine, 2009; Papi et al., 2003; Tsujikawa et al., 2004). Of these patients, eight were male and the remaining nine were female, and their mean age was 41.59 ± 23.93 years. None of these patients had received infliximab treatment before. Most of the patients showed multiple potential bleeding sites, of which the ileum (n = 7) and ileocolon (n = 7) were the most common disease locations (Zeng et al., 2022; Akazawa et al., 2014; Ando et al., 2009; Aniwan et al., 2012; Belaiche and Louis, 2002; Cunningham et al., 2014; Meyer and Levine, 2009; Papi et al., 2003; Tsujikawa et al., 2004). Three of these patients received surgery but did not show significantly improved hematochezia, and two of them had undergone multiple surgeries. All patients received infliximab therapy when the conventional treatments and surgery could not stanch the bleeding effectively. Eight patients achieved the goal of hemostasis within 1 week and received only one course of infliximab treatment. Four of the patients had metastasized on the day of first infliximab therapy but still finished the second course. One patient experienced bleeding stoppage with accelerated infliximab induction; two patients achieved hemostasis after approximately 2 weeks of infliximab therapy, and five patients received long-term maintenance therapy (Supplementary Table S3).

Our study has some notable limitations, including the limited number of cases, which could affect the reliability of the results. In addition, the grouping of cases into different treatment plans was not random but rather determined based on patient preferences and clinical evaluations. Lastly, this study was conducted retrospectively and is therefore prone to bias from unrecognized or unmeasured factors, such as recall bias. Nevertheless, the strength of our present study is that we report and utilize a well-defined inception cohort, which enables us to evaluate the efficacies and economic issues associated with infliximab therapy, surgery, and conventional therapy for CD patients with acute SLGIB; we also conducted long-term follow-up on the patients. The present work is a multicenter study conducted in Hunan Province of China, and our results are consistent with the findings of a previous study by Kim et al. (2021). The earlier study only analyzed the efficacy of hemostasis and rebleeding risk, whereas our research additionally compares Hb level improvements, anti-inflammatory effects, and rate of complications, along with the duration and cost of hospitalization among the different groups.

Our findings suggest that infliximab therapy is an effective method for controlling acute SLGIB in CD patients and that it may be better than surgery and traditional treatment in terms of anti-inflammatory effects and rebleeding prevention. Furthermore, the cost and duration of hospitalization in the infliximab therapy group are similar to those in the traditional treatment group and lower than those in the surgery group. In conclusion, infliximab therapy should be considered in clinical practice for acute SLGIB in CD to achieve better prognosis and economic benefits.

Acknowledgements

The authors wish to thank all the investigators and patients who contributed to this study.

Funding Statement

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Natural Science Foundation of China (no. 82270594), Outstanding Youth Foundation of Hunan Province (no. 2022JJ20092), Science and Technology Innovation Program of Hunan Province (no. 2024RC3065), and Wisdom Accumulation and Talent Cultivation Project of Third Xiangya Hospital of Central South University (no. YX202103).

Footnotes

Edited by: Thomas Brzozowski, Jagiellonian University Medical College, Poland

Reviewed by: Azna Zuberi, Northwestern University, United States

Ryma Toumi, Seattle Children’s Research Institute, United States

Paul Rufo, Boston Children’s Hospital and Harvard Medical School, United States

Harikrishna Choudary Ponnam, Summa Health System, Akron, United States

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors without undue reservation.

Ethics statement

The studies involving humans were approved by the Clinical Research Ethics Committee of the Third Xiangya Hospital of Central South University. The studies were conducted in accordance with all local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or their legal guardians/next of kin because of the retrospective nature of the study. Furthermore, the Clinical Research Ethics Committee of the Third Xiangya Hospital of Central South University waived the need for obtaining informed consent.

Author contributions

SY: Formal analysis, Resources, Data curation, Writing – original draft, Validation, Writing – review and editing, Methodology. ZW: Validation, Methodology, Data curation, Writing – review and editing, Writing – original draft, Resources, Formal analysis. MX: Resources, Writing – review and editing, Methodology. SW: Resources, Writing – review and editing, Methodology. YF: Writing – review and editing, Methodology, Resources. XL: Conceptualization, Project administration, Funding acquisition, Supervision, Writing – review and editing. FW: Supervision, Writing – review and editing, Funding acquisition, Project administration, Conceptualization.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2026.1687439/full#supplementary-material

Supplementaryfile1.docx (30.5KB, docx)

References

  1. Akazawa Y., Takeshima F., Yajima H., Imanishi D., Kanda T., Matsushima K., et al. (2014). Infliximab therapy for Crohn's-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report. BMC Res. Notes 7, 382. 10.1186/1756-0500-7-382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ando Y., Matsushita M., Kawamata S., Shimatani M., Fujii T., Okazaki K. (2009). Infliximab for severe gastrointestinal bleeding in crohn's disease. Inflamm. Bowel Dis. 15 (3), 483–484. 10.1002/ibd.20635 [DOI] [PubMed] [Google Scholar]
  3. Aniwan S., Eakpongpaisit S., Imraporn B., Amornsawadwatana S., Rerknimitr R. (2012). Infliximab stopped severe gastrointestinal bleeding in Crohn's disease. World J. Gastroenterol. 18 (21), 2730–2734. 10.3748/wjg.v18.i21.2730 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Atreya R., Siegmund B. (2021). Location is important: differentiation between ileal and colonic Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 544–558. 10.1038/s41575-021-00424-6 [DOI] [PubMed] [Google Scholar]
  5. Attauabi M., Steenholdt C., Poulsen A., Gubatan J., Burisch J., Nielsen O. H., et al. (2024). Network meta-analysis: comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease. Aliment. Pharmacol. Ther. 60 (2), 124–143. 10.1111/apt.18110 [DOI] [PubMed] [Google Scholar]
  6. Balderramo D., Trakal J., Herrera Najum P., Vivas M., Gonzalez R., Benavidez A., et al. (2021). High ulcerative colitis and Crohn's disease ratio in a population-based registry from Cordoba, Argentina. Dig. Liver Dis. 53 (7), 852–857. 10.1016/j.dld.2021.01.006 [DOI] [PubMed] [Google Scholar]
  7. Baumgart D. C., Le Berre C. (2021). Newer biologic and small-molecule therapies for inflammatory bowel disease. N. Engl. J. Med. 385 (14), 1302–1315. 10.1056/NEJMra1907607 [DOI] [PubMed] [Google Scholar]
  8. Belaiche J., Louis E. (2002). Severe lower gastrointestinal bleeding in Crohn's disease: successful control with infliximab. Am. J. Gastroenterol. 97 (12), 3210–3211. 10.1111/j.1572-0241.2002.07143.x [DOI] [PubMed] [Google Scholar]
  9. Bon C., Aparicio T., Vincent M., Mavros M., Bejou B., Raynaud J. J., et al. (2012). Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Alimentary Pharmacol. and Ther. 36 (6), 587–593. 10.1111/apt.12000 [DOI] [PubMed] [Google Scholar]
  10. Cassol O. S., Zabot G. P., Saad-Hossne R., Padoin A. (2022). Epidemiology of inflammatory bowel diseases in the state of Rio Grande do Sul, Brazil. World J. Gastroenterology 28 (30), 4174–4181. 10.3748/wjg.v28.i30.4174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cunningham G., Cameron G., De Cruz P. (2014). Hepatic portal venous gas in Crohn's disease. BMJ Case Rep. 2014, 2014. 10.1136/bcr-2014-206244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gibson D. J., Heetun Z. S., Redmond C. E., Nanda K. S., Keegan D., Byrne K., et al. (2015). An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 13 (2), 330–335.e1. 10.1016/j.cgh.2014.07.041 [DOI] [PubMed] [Google Scholar]
  13. Gibson D. J., Doherty J., McNally M., Campion J., Keegan D., Keogh A., et al. (2020). Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterol. 11 (6), 441–447. 10.1136/flgastro-2019-101335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hutfless S., Jasper R. A., Chen P. H., Joseph S., Miller S., Brant S. R. (2024). Burden of Crohn's disease in the United States medicaid population, 2010-2019. Clin. Gastroenterol. Hepatol. 22 (5), 1087–1097.e6. 10.1016/j.cgh.2023.05.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jenkinson P. W., Plevris N., Siakavellas S., Lyons M., Arnott I. D., Wilson D., et al. (2020). Temporal trends in surgical resection rates and biologic prescribing in Crohn's disease: a population-based cohort study. J. Crohns Colitis 14 (9), 1241–1247. 10.1093/ecco-jcc/jjaa044 [DOI] [PubMed] [Google Scholar]
  16. Kim K. J., Han B. J., Yang S. K., Na S. Y., Park S. K., Boo S. J., et al. (2012). Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn's disease. Dig. Liver Dis. 44 (9), 723–728. 10.1016/j.dld.2012.03.010 [DOI] [PubMed] [Google Scholar]
  17. Kim D. S., Yoon J., Kim Y. J., Lee J. W., Hong S. W., Hwang H. W., et al. (2021). Risk factors for rebleeding in Crohn's disease patients with acute severe lower gastrointestinal bleeding: with special reference to the role of anti-tumor necrosis factor therapy. J. Gastroenterol. Hepatol. 36 (9), 2455–2462. 10.1111/jgh.15495 [DOI] [PubMed] [Google Scholar]
  18. Lavy A., Yasin K. (2003). Octreotide for enterocutaneous fistulas of Crohn's disease. Can. J. Gastroenterology 17 (9), 555–558. 10.1155/2003/645751 [DOI] [PubMed] [Google Scholar]
  19. Lee S., Ye B. D., Park S. H., Lee K. J., Kim A. Y., Lee J. S., et al. (2018). Diagnostic value of computed tomography in Crohn's disease patients presenting with acute severe lower gastrointestinal bleeding. Korean J. Radiol. 19 (6), 1089–1098. 10.3348/kjr.2018.19.6.1089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Meyer M. M., Levine E. J. (2009). Acute hemorrhagic Crohn's disease controlled with infliximab. Inflamm. Bowel Dis. 15 (10), 1456–1457. 10.1002/ibd.20840 [DOI] [PubMed] [Google Scholar]
  21. Narula N., Chang N. H., Mohammad D., Wong E. C. L., Ananthakrishnan A. N., Chan S. S. M., et al. (2023). Food processing and risk of inflammatory bowel disease: a systematic review and meta-analysis. Clin. Gastroenterology Hepatology 21 (10), 2483–2495. 10.1016/j.cgh.2023.01.012 [DOI] [PubMed] [Google Scholar]
  22. Omede M., Itam-Eyo A., Park A., Ikobah J., Ibrahim M. K., Chukwudike E., et al. (2025). Epidemiology, natural history and treatment of IBD in Africa: a scoping review. Clin. Gastroenterology Hepatology 24 (1), 41–56. 10.1016/j.cgh.2024.12.036 [DOI] [PubMed] [Google Scholar]
  23. Papi C., Gili L., Tarquini M., Antonelli G., Capurso L. (2003). Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage. J. Clin. Gastroenterol. 36 (3), 238–241. 10.1097/00004836-200303000-00011 [DOI] [PubMed] [Google Scholar]
  24. Park J., Cheon J. H. (2021). Incidence and prevalence of inflammatory bowel disease across Asia. Yonsei Med. J. 62 (2), 99–108. 10.3349/ymj.2021.62.2.99 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Poulsen A., Rasmussen J., Wewer M. D., Holm Hansen E., Nordestgaard R. L. M., Søe Riis Jespersen H., et al. (2024). Re-resection rates and disease recurrence in Crohn's disease: a population-based study using individual-level patient data. J. Crohns Colitis 18 (10), 1631–1643. 10.1093/ecco-jcc/jjae070 [DOI] [PubMed] [Google Scholar]
  26. Sands B. E., Danese S., Chapman J. C., Gurjar K., Grieve S., Thakur D., et al. (2024). Mucosal and transmural healing and long-term outcomes in Crohn's disease. Inflamm. Bowel Dis. 31 (3), 857–877. 10.1093/ibd/izae159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shinagawa T., Hata K., Ikeuchi H., Fukushima K., Futami K., Sugita A., et al. (2020). Rate of reoperation decreased significantly after year 2002 in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 18 (4), 898–907. 10.1016/j.cgh.2019.07.025 [DOI] [PubMed] [Google Scholar]
  28. Suau R., Pardina E., Domènech E., Lorén V., Manyé J. (2022). The complex relationship between microbiota, immune response and creeping fat in Crohn's disease. J. Crohns and Colitis 16 (3), 472–489. 10.1093/ecco-jcc/jjab159 [DOI] [PubMed] [Google Scholar]
  29. Takenaka K., Kawamoto A., Hibiya S., Suzuki K., Fujii T., Motobayashi M., et al. (2021). Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Aliment. Pharmacol. Ther. 54 (8), 1052–1060. 10.1111/apt.16551 [DOI] [PubMed] [Google Scholar]
  30. Tamagno G., Mioni R., De Carlo E., Maffei P., Rubello D., Sicolo N. (2004). Effects of a somatostatin analogue in occult gastrointestinal bleeding: a case report. Dig. Liver Dis. 36 (12), 843–846. 10.1016/j.dld.2004.01.028 [DOI] [PubMed] [Google Scholar]
  31. Tsujikawa T., Nezu R., Andoh A., Saotome T., Araki Y., Ishizuka Y., et al. (2004). Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease. J. Gastroenterol. 39 (3), 284–287. 10.1007/s00535-003-1290-9 [DOI] [PubMed] [Google Scholar]
  32. Tu T., Chen M., Zeng Z., Lin J., Chen L., Liu C., et al. (2024). A comprehensive review and update on acute severe lower gastrointestinal bleeding in Crohn's disease: a management algorithm. Gastroenterol. Rep. (Oxf) 12, goae099. 10.1093/gastro/goae099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Yoon J., Kim D. S., Kim Y. J., Lee J. W., Hong S. W., Hwang H. W., et al. (2021). Risk factors and prognostic value of acute severe lower gastrointestinal bleeding in Crohn's disease. World J. Gastroenterol. 27 (19), 2353–2365. 10.3748/wjg.v27.i19.2353 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yu B., Zhao L., Jin S., He H., Zhang J., Wang X. (2022). Model-based meta-analysis on the efficacy of biologics and small targeted molecules for Crohn's disease. Front. Immunol. 13, 828219. 10.3389/fimmu.2022.828219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yu Q., Funaki B., Ahmed O. (2024). Twenty years of embolization for acute lower gastrointestinal bleeding: a meta-analysis of rebleeding and ischaemia rates. Br. J. Radiol. 97 (1157), 920–932. 10.1093/bjr/tqae037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Zeng J., Shen F., Fan J. G., Ge W. S. (2022). Accelerated infliximab induction for severe lower gastrointestinal bleeding in a young patient with Crohn's disease: a case report. World J. Clin. Cases 10 (2), 733–740. 10.12998/wjcc.v10.i2.733 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementaryfile1.docx (30.5KB, docx)

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors without undue reservation.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES